Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

NCT02718300 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT02718300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02718300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Terminated
Start date
February 8, 2017
Completion date
April 29, 2022
Enrollment
74 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

mpn (myeloproliferative neoplasms)